Background: Antiviral drugs of the category of nucleoside reverse transcriptase inhibitors (NRTIs), largely used for the treatment of HIV infection, can have toxic effects on mitochondria. We performed a cross-sectional study on mitochondrial toxicity in a randomized group of patients belonging to a larger randomized study on different NRTIbased once-daily regimens by quantifying mitochondrial DNA (mtDNA), three different mitochondrial RNAs (mtRNAs) and functional parameters in highly purified peripheral CD4 + and CD8 + T-cells. Methods: A total of 49 previously treatment-naive patients treated for a mean of 15 months with efavirenz plus didanosine plus lamivudine (group 1), or tenofovir disoproxil fumarate plus lamivudine (group 2), or didanosine plus abacavir (group 3) were considered. The groups were matched for sex, age, CDC classification, risk factor for HIV, nadir CD4 + T-cell count and baseline viral load. mtDNA and mtRNA were quantified by using real-time PCR assays. Results: No patient showed any clinical symptom; however, the amount of mtDNA in CD4 + and CD8 + T-cells was significantly lower in groups 1 and 3; similarly, the expression of different mtRNAs in both CD4 + and CD8 + T-cells showed significant differences that were dependent upon the drug used. No differences were found in mitochondrial membrane potential and mitochondrial mass in peripheral lymphocytes. The amount of total HIV DNA in CD4 + T-cells did not differ among the groups, who displayed a similar immune reconstitution and control of the virus. Conclusions: An efficient didanosine-containing once-daily therapy can have more mitochondrial toxicity than regimens devoid of this drug.
Nucleoside reverse transcriptase inhibitors (NRTIs) are widely used, in combination with other drugs, in the highly active antiretroviral therapy (HAART) for HIV infection. Their use is associated with several side effects that could be acute, such as cephalalgia, gastrointestinal troubles and hypersensivity reactions, or chronic, such as diabetes, depression, neuropathy and anaemia [1] . Some of these effects have been ascribed to drug toxicity for mitochondria [2, 3] . Indeed, NRTIs can bind the mitochondrial-specific γ-polymerase and alter its functionality [4] . Because this enzyme is responsible for the replication of mitochondrial DNA (mtDNA), its inhibition can lead to a decrease in mtDNA content and consequently to an impairment in the production of the respiratory enzymes required for mitochondrial function.
Several studies in HIV-positive patients taking NRTIs described a depletion of mtDNA in several tissues, such as skeletal muscle, adipose tissue, liver, peripheral nerves and placenta, and in platelet-free peripheral blood lymphocytes or peripheral blood mononuclear cells (PBMCs) [5] [6] [7] [8] [9] [10] . However, contrasting data exist on either the amount or the meaning of changes in mtDNA content in peripheral blood cells during antiretroviral treatment. Some of the controversies present in the literature can be ascribed to different variables that are present in the experimental systems used [11] . For example, systems that use highly purified and cultured + or CD8 + T-lymphocytes) can behave differently as far as the sensitivity to drugs is concerned [12] . The analysis of mtDNA in unsorted PBMCs are often disturbed by the presence of platelets, that contain mtDNA [13] . Different rates of drug uptake and phosphorylation among cell types could be in part responsible for the different toxicity observed in different tissues [14] . Finally, the age of the patients can also play a role in the sensitivity of mitochondria to antiretrovirals [15, 16] . Thus, discussions are still ongoing regarding whether the quantification of mtDNA in peripheral blood cells, which are obviously much easier to obtain in comparison with other tissues or organs (for example, liver or kidney), could be considered a good marker of a generalized mitochondrial damage.
To better identify alterations occurring to mitochondria, it can be of interest to monitor other parameters than mtDNA that can provide further information on the functionality of the organelle. In particular, it has been shown that the expression of mitochondrial messenger RNAs (mRNAs; such as ND1, encoding for the subunit 1 of the NADH-dehydrogenase complex, CytB, encoding for the cytochrome B and ND6, encoding for the subunit 6 of the NADH-dehydrogenase complex) can be useful to evaluate the efficiency of RNA transcription from mtDNA [17] . Indeed, recently we quantified these mRNAs in different cell lines treated with NRTIs and found a decrease in their transcription that was dependent on cell type and drug [17] . A similar decrease of mitochondrial RNA (mtRNA) was observed in adipose tissue from patients with lipodystrophy [18] , or in monocytes from healthy donors treated with NRTIs [19] .
To monitor mitochondrial functionality, functional markers can also be used in living intact cells, such as mitochondrial membrane potential (∆ψ m ) and mitochondrial mass [15, 20] . It has been shown that zidovudine and stavudine can cause changes in ∆ψ m and increase mitochondrial-driven apoptosis [21] . Some of these effects can be prevented by molecules such as acetyl-l-carnitine [22] .
To evaluate the mitochondrial toxicity of once-daily therapies containing different NRTIs, we evaluated the aforementioned parameters in peripheral blood CD4 + and CD8 + T-cells from three groups of patients taking efavirenz plus different combinations of didanosine (ddI), lamivudine, tenofovir disoproxil fumarate and abacavir. Furthermore, because HIV infection itself can be responsible for mitochondrial damages, we also quantified the amount of viral DNA in highly purified CD4 + T-cells to distinguish the potentially toxic effects of the virus on mitochondria from those provoked by the drugs.
Methods

Patients
We studied a total of 49 patients treated with a oncedaily therapy based on three different combinations of antiretroviral drugs. All patients assumed efavirenz and ddI plus lamivudine (18 patients, group 1), or lamivudine plus tenofovir disoproxil fumarate (16 patients, group 2), or ddI plus abacavir (15 patients, group 3). All of them were on their first HAART regimen and were enrolled in a larger randomized prospective controlled clinical trial.
In the three groups, patients were matched for sex, age, length of therapy, nadir CD4 + T-cell count and baseline HIV RNA; furthermore, no differences were present in terms of CDC stage or risk factors for HIV infection (data not shown), CD4 + T-cell count, lipidic and glucidic profiles at the moment of blood collection for the study (Table 1) .
Peripheral blood (between 10 and 25 ml) anticoagulated with EDTA was collected in the Division of Infectious Diseases, Ospedali Riuniti, Bergamo, Italy, between 8 and 9 am, coded and then immediately taken by car at room temperature to the laboratories of the Infectious Diseases Clinic, Modena, Italy, for either the functional analysis or the quantification of mtDNA and mtRNA. In all experiments, blood was processed within 3 h of the collection, and operators were blind with respect to the group the patients had been randomized to. Indeed, codes were open only at the end of all the biological analyses.
Peripheral blood lymphocyte isolation
PBMCs were obtained by standard methods after centri fugation on Ficoll density gradient. CD4 + or CD8 + T-cells were then isolated first by monocyte removal (by plastic adhesion for 1 h at 37°C) and then by magnetic sorting (using monoclonal antibodies; Miltenyi GmbH, Bergisch Gladbach, Germany); this allowed an almost complete elimination of platelet contamination, which is normally present after density gradient centrifugation [13] . Indeed, as assessed in parallel samples by cytofluorimetric analysis, the purity of T-cell populations was always >95%, with a platelet contamination <1%.
Quantification of mitochondrial DNA
The cell content of mtDNA in CD4 + and CD8 + T-cells was measured by a method based on real-time PCR, using two PCRs that quantify mtDNA and nuclear DNA (nDNA) at the same time by the same construct; known amounts of both were amplified as reference molecules (mtDNA qKit; Genemore Italy srl, Modena, Italy), as described [12] . The reactions were performed by using an iQ5 Real Time PCR system (Bio-Rad, Hercules, CA, USA).
Quantification of mitochondrial RNA
The relative amount of three mitochondrial transcripts (ND1, CytB and ND6) was measured using a realtime approach (mtRNA qKit; Genemore Italy srl). As described, the amplicons of interest (derived from ND1, CYTB, ND6 and L13 genes, the latter used as housekeeping mRNA) were cloned together in a plasmid in order to obtain a single reference DNA molecule to be used as the standard for the real-time PCR quantification of all four transcripts [17] . Using TaqMan-based real-time PCR, each different transcript was quantified in a separate reaction to avoid non-specific amplifications and to ensure the maximal reliability of the study. The reactions were performed in an iQ5 Real Time PCR system.
Mitochondrial mass and mitochondrial membrane potential
In some patients, the amount of cells obtained from density gradient centrifugation allowed us to evaluate, on freshly collected PBMCs, not only mtDNA and mtRNA (that were, however, quantified in isolated CD4 + or CD8 + T-lymphocytes), but also their mass and ∆ψ m , two parameters related to mitochondrial functionality. For the analysis of ∆ψ m , freshly collected cells were resuspended in complete medium (RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum, 2 mM l-glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin (all from Gibco BRL, Life Technologies, Paisley, Scotland), and then stained with the ∆ψ m highly specific probe JC-1 (Molecular Probes, Eugene, OR, USA) [23] , used at a final concentration of 10 µM, as previously described [24, 25] .
The analysis of the mitochondrial mass was performed using the probe nonyl acridine orange (NAO), which binds in a stoichiometric manner to cardiolipin, a phospholipid almost exclusively present in the inner mitochondria membrane [26] . PBMCs were resuspended in complete medium and stained with NAO at the final concentration of 10 µM, at room temperature in the dark for 10 min, and analysed by flow cytometry, as described [26] . PBMCs were stained as described above and immediately analysed; at least 10,000 events inside the lymphocyte gate were acquired for each sample, and the few dead cells were eliminated from the analysis. We used a 16-parameter Cyflow ML flow cytometer (Partec GmbH, Münster, Germany), equipped with a blue solid state laser (488 nm, 200 mW, kept at 50 mW), a red diode laser (635 nm, 25 mW), a violet solid state laser (405 nm, 25 mW), a UV Mercury lamp HBO (100 long life, 100 W), a green solid state laser (532 nm, 100 mW) and a CCD camera. Data were acquired and analysed by Flomax 3.0 (Partec) under Microsoft Windows, and FlowJo 6.3 (Treestar Inc., Ashland, OR, USA) under Mac OS X 10.5.7 [24] .
Quantification of viral DNA
Intracellular HIV DNA was measured in purified CD4 + T-cells using a recently developed assay (Intracellular HIV DNA qPCR kit; GeneMoRe Italy srl) [27] . The test uses two parallel reactions that quantify HIV DNA and nDNA for any given sample, in order to normalize the number of copies of intracellular viral DNA to the number of starting cells [16, 17] . Briefly, for HIV DNA, real-time PCR was performed in a 25 µl reaction mix containing 12.5 µl of Platinum UDG Real-Time PCR Supermix 2X (Invitrogen, Carlsbad, CA, USA), primers long terminal repeat (LTR) DIR (5′-GCCTCAATAAAGCTTGCCTTGA-3′) 200 nM, LTR REV (5′-GGGCGCCACTGCTAGAGA-3′) 200 nM and TaqMan Probe LTRprobe (5′-FAM-CCAGAGT-CACACAACAGACGGGCACA-BHQ1-3′) 300 nM. nDNA was quantified with a previously described method [12] . Both reactions were performed in an iQ5 Real-Time PCR system, and as a standard for quantification either of HIV DNA and nDNA we used a plasmid in which both amplicons were cloned tail-to-tail to have a 1:1 ratio between them. Plasmid was used during reactions in scalar dilutions to build a standard curve, used as a reference to calculate the number of copies of HIV DNA or nDNA of unknown samples. HIV DNA values were normalized to corresponding nDNA, multiplied by two, as two copies of every nuclear gene are obviously present in each normal cell. Data were then expressed as number of HIV DNA copies/10 6 cells.
Statistical analysis
Statistical analysis was performed on Graph Pad Prism 4.0 using the Kruskal-Wallis test (for the test among all groups) and the Mann-Whitney U test to analyse the differences between groups. A general linear procedure providing regression analysis and analysis of variance was used to test the null hypothesis about the effects of baseline variables on mitochondrial toxicity data. Values of P<0.05 were considered statistically significant.
Results
Quantification of mtDNA in CD4 + and CD8 + T-cells
As shown in Figure 1A , mtDNA content in CD4 + T-lymphocytes were significantly related to the therapy (P=0.002). Indeed, group 1 showed a mean ±sd 35.13 ±20.28 mtDNA copies/cell, group 2 had 79.15 ±33.88 copies/cell and group 3 had 31.88 ±12.82 copies/cell. Using the Kruskal-Wallis test among the three groups, we found a highly significant value (P<0.0001); variance analysis between pairs of groups revealed that group 2 was responsible for this difference, having a mean value much higher than the others (P<0.0001 versus both groups 1 and 3). No differences were found between groups 1 and 3. Similarly, the analysis of mtDNA content in CD8 + T-cells revealed a correlation with the type of therapy (P=0.01), with a mean ±sd of 35.83 ±24.36 mtDNA copies/cell for group 1, 73.09 ±61.59 copies/cell for group 2 and 25.87 ±13.4 copies/cell for group 3 ( Figure 1B) . As in the case of CD4 + T-cells, the Kruskal-Wallis test was significant (P=0.014), and group 2 was responsible for the difference (P=0.036 and P=0.006 versus groups 1 and 3, respectively). We did not find any difference between groups 1 and 3. Figure 2A shows that a significant correlation (P<0.0001) exists between the number of mtDNA copies/cell in CD4 + and CD8 + T-cells, indicating that the type of therapy have the same effect on both cell types.
As far as metabolic parameters are concerned, we found an inverse correlation between total cholesterol levels and mtDNA copies/cells in both CD4 + (P<0.001) and CD8 + (P=0.001) T-cells ( Figure 2B and 2C, respectively). Correlations were not found for triglycerides and blood sugar levels.
Finally, using multivariate analysis, we found no correlations between the mtDNA content in CD4 + or CD8 + T-cells and immunovirological or haematological parameters (data not shown). 
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+ T-cells. Group 1 (n=18 patients), assuming efavirenz (EFV) plus didanosine (ddI) plus lamivuidine (3TC), group 2 (n=16 patients), assuming EFV plus 3TC plus tenofovir disoproxil fumarate and group 3 (n=15 patients), assuming EFV plus ddI plus abacavir. The bottom and top of the boxes indicate the 25th and 75th percentiles, respectively, and the band within each box is the median; the ends of the whiskers represent the minimum and maximum of all the data. 
Quantification of mitochondrial RNA
The relative amount of three mitochondrial mRNAs, calculated as the number of copies of mitochondrial mRNA/copies of L13 (a nuclear mRNA that is expressed at constant levels by lymphocytes), was measured in CD4 + and CD8 + T-cells (Figure 3) . In CD4 + T-lymphocytes, no differences were found in the expression of ND1, whereas the expression of CytB and ND6 were higher in group 2 when compared with the others. The expression of ND6 was also different between groups 1 and 3.
The same analysis in CD8 + T-cells revealed a higher expression of all three mitochondrial mRNA in group 2 compared with the others. In both CD4
+ and CD8 + T-cells, the group 2 was responsible for the differences in the expression of mitochondrial mRNA. Finally, no correlation was found between the amount of mtDNA and the expression of ND1, CytB and ND6 in both CD4 + and CD8 + T-cells (data not shown).
Mitochondrial mass and mitochondrial membrane potential
Because of the amount of blood we could obtain from each patient and the available number of PBMCs, the analysis of ∆ψ m was performed in 11 patients from group 1, 5 from group 2 and 8 from group 3. No differences were found in the percentage of cells with depolarized mitochondria (low ∆ψ m ) among the groups, nor in the amount of mitochondrial mass (measured as relative fluorescence units; data not shown). Moreover, no significant correlations were found between mtDNA content (or mtRNA content) and mitochondrial mass or potential (data not shown).
Quantification of viral DNA, plasma viral load and CD4 + T-cell count
The quantification of the copies of viral DNA per million of CD4 + T-cells did not reveal any difference among the three groups of patients. Indeed, group 1 had a median of 13,938 HIV DNA copies/million cells (interquartile range [IQR] 11,498), group 2 had a median of 13,953 HIV DNA copies/million cells (IQR 13,587) and group 3 had a median of 12,582 HIV DNA copies/ million cells (IQR 15,079; P=non-significant).
This result, indicating that the therapy had a similar efficacy in all patients, is corroborated by the measure of plasma viral load, invariably below the detection limit of 50 copies/ml, and by the CD4 + T-cell counts (Table 1) , which were similar in all the groups.
Discussion
The aim of this study was to analyse possible effects on mitochondria of different once-daily regimens in HIV-positive treatment-naive patients. With regards to immunovirological parameters, all treatments had a similar effect, as in all cases it was possible to observe a consistent decrease in plasma viral load along with an increase in CD4 + T-cell count. Moreover, the intracellular viral load, measured as the amount of HIV DNA present within CD4 + T-cell, was similar in all groups, indicating the same extent of suppression of viral production in all groups.
With regards to the analysis of mtDNA and mtRNA, the quantification of mtDNA in CD4 + and CD8 + T-cells was a reliable marker of drug toxicity for mitochondria, at least for highly purified CD4 + and CD8 + T-lymphocytes. However, we are well aware that this result is limited to these types of cells, and that at present no direct link has been found between mtDNA depletion in T-lymphocytes and in other cell types. In any case, it has to be noted that careful attention was paid to the removal of platelets, whose presence can heavily influence the quantification of mtDNA and mtRNA [13] . We found that, in both cell types, the number of mtDNA copies/cell was lower in groups 1 and 3 when compared with group 2. Because the latter group was the only one in which patients were not treated with ddI, it is possible to hypothesize that the decrease in mtDNA was caused by the toxic action of this drug, which is known to have a higher capacity to inhibit γ-polymerase if compared with abacavir or tenofovir disoproxil fumarate [28, 29] . Different studies have pointed out the possible meaning and utility of the analysis of mtDNA for detecting drug toxicity [30, 31] , showing that NRTIs differ one from another in their ability to reduce mtDNA content [32, 33] . According to other findings in PBMCs from children receiving HAART, it was shown that ddI was the only drug associated with a decrease in mtDNA content [34] . In cells from adipose tissue, alterations of mtDNA levels were found in HIV-positive patients affected by lipodystrophy when compared with treated or untreated HIV-infected patients, and with HIV-negative controls [35, 36] . One study has shown correlations between mtDNA levels, both in PBMCs and in adipose tissue [37] . More recently, a fourfold increase in the mtDNA content of adipocytes was demonstrated in patients switching from stavudine to tenofovir disoproxil fumarate [38] .
The results obtained by measuring mtRNA strongly supported observations at the mtDNA level, as in this case we also found significant decreases in ddI-treated patients (namely groups 1 and 3) by comparison with the others (group 2). The quantification of mitochondrial messengers can provide further information on the functionality of mtDNA because a reduced ability to transcribe mtDNA could lead to an impairment in the synthesis of the enzymes of the respiratory chain encoded by mtDNA. Interestingly, changes in mtRNA expression can be present before the appearance of damages to mtDNA [17, 19] .
The mitochondrial genome is characterized by the absence of introns; the genes are separated by small spacers and are transcribed as two polycistronic units that are then processed by an endonuclease to form the single mtRNAs. The quantification of mitochondrial messengers can reveal the efficiency of the transcription machinery into the mitochondria. Because ND1 and CytB are both encoded on the heavy strand of mtDNA, we should expect to find the same amount of these messengers in the cells, even if the rate of degradation could be different and could influence the ratio. Because ND6 is transcribed from the light chain, the simultaneous measurement of these three messengers provides information about the global functionality of the transcription in the organelle.
In CD4 + T-cells, no differences were found in the amount of ND1 mRNA among the groups, whereas a higher expression of CytB was found in group 2. ND1 and CytB are sequentially transcribed, so we hypothesized that the toxic effect of the drugs in group 1 and 3 leads to a progressive reduction in mtDNA transcription. Therefore the first gene, ND1, was transcribed with a higher efficiency than CytB causing a significant change in the expression of CytB in group 1 and 3 when compared with group 2. The amount of ND6 was lower in group 3 compared with groups 2 and 1, but no differences were found between groups 1 and 2.
In CD8 + T-cells, the expression of all the messengers were significantly higher in group 2 compared with groups 1 and 3. The effect of ddI thus seems more evident on CD8
+ cells, where a reduced transcription of mtDNA was found on both the heavy and light chain.
The molecular quantification of mtDNA and mtRNA was accompanied by the functional analysis of the behaviour of the organelle, as we measured ∆ψ m and mitochondrial mass. We found no main effects of any drug treatment in freshly collected PBMCs. This can be ascribed to two possible, not mutually exclusive reasons. The first could be related to the relatively small number of samples we could analyse, and to their high variability. The second could be related to the notion that, as recently observed in muscular pathologies, a much higher loss of mtDNA has to occur in order to detect a functional damage [39] [40] [41] .
Finally, an inverse correlation was found between the amount of mtDNA in both CD4 + and CD8 + T-cells and cholesterolaemia. Increasing evidence supports the relationship between mitochondrial DNA variability and differences in energy metabolism, which might have pathophenotypic consequences [42] . mtDNA pathological mutation has also been described to be associated with hypercholesterolaemia [43] . In our study, we focused our attention on quantitative aspects concerning mtDNA, and the relationship with metabolic parameters, and thus this molecule has been quantified by using the most advanced technology. Changes in mtDNA content in peripheral blood cells have been described in different metabolic alterations, including diabetes mellitus [44] . Interestingly, it has been found that, in young healthy men, mtDNA content shows an inverse correlation with different indices of insulin resistance and insulin secretion [45] , or with the area under the curve of insulin during an oral glucose tolerance test [46] . Furthermore, in healthy women, a negative correlation has been found between plasma concentrations of homocysteine (a well-known risk factor for atherosclerosis in coronary, cerebral and peripheral vascular diseases) and the mtDNA content of peripheral blood cells [47] . Interestingly, the same study also describes the presence of a negative correlation between mtDNA and total cholesterol, low-density lipoprotein cholesterol or triglyceride, but not highdensity lipoprotein cholesterol. Our data are in full agreement with the aforementioned observations, as we found an indirect correlation with highly purified blood cells, such as CD4 + and CD8 + T-lymphocytes. Mitochondria are key organelles for the steroidogenesis, and indeed the first and limiting step in the biosynthesis of steroid hormones is the transfer of cholesterol across the intermembrane space, from the outer to the inner mitochondrial membrane, a process finely tuned by the action of specific proteins, such as the steroidogenic acute regulatory protein [48] . Thus, it is possible to hypothesize that drug-induced mitochondrial damages, which can be mediated by the intramitochondrial production of oxygen free radicals, lead to alterations of the cholesterol metabolism. By contrast, it is also possible that, as shown in macrophages, the accumulation of free cholesterol can be associated with mitochondrial dysfunction, along with the activation of caspases that lead to apoptosis [49] . Thus, metabolic alteration can, in turn, take to mitochondrial damages, thereby starting a vicious circle that could become, at least in part, responsible of some of the alterations typically present during lipodystrophy. However, the data regarding the inverse correlation between mtDNA and cholesterolaemia are partially in contrast with what was observed in HIVpositive patients with lipodystrophy, who showed a positive correlation between mtDNA levels in CD4 + T-cells and cholesterolaemia [50] . Even if the clinical conditions of the patients here described are markedly different from those with lipodystrophy, and considering that in both studies several patients had hypercholesterolaemia, further studies are needed to investigate this aspect and clarify which biological relationship(s) exist between mtDNA content in peripheral blood lymphocytes and plasma cholesterol levels.
